May 17, 2017 review Open access Paroxysmal nocturnal haemoglobinuria Nature Reviews Disease Primers DOI: 10.1038/nrdp.2017.28 Full text (OA) OpenAlex Authors 0 Author list not loaded yet. Cited by 21 stored of 454 Search Sort Most cited Newest Oldest Patent citations Title Any typearticle review book-chapter conference-paper preprint dissertation book dataset other Any fieldAgricultural and Biological Sciences Arts and Humanities Biochemistry, Genetics and Molecular Biology Business, Management and Accounting Chemical Engineering Chemistry Computer Science Decision Sciences Dentistry Earth and Planetary Sciences Economics, Econometrics and Finance Energy Engineering Environmental Science Health Professions Immunology and Microbiology Materials Science Mathematics Medicine Neuroscience Nursing Pharmacology, Toxicology and Pharmaceutics Physics and Astronomy Psychology Social Sciences Veterinary Open access Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti‐C5 therapy 2026 HemaSphere article Immunology and Microbiology Complement system in diseases Open access 0 citations Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies 2025 Annals of Hematology article Immunology and Microbiology Complement system in diseases Open access 1 citations Autoantibodies and therapeutic antibodies against complement factor H 2025 Immunology Letters article Immunology and Microbiology Complement system in diseases Open access 6 citations Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria 2025 British Journal of Clinical Pharmacology article Immunology and Microbiology Complement system in diseases Open access 10 citations Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment 2024 Transfusion Medicine and Hemotherapy article Immunology and Microbiology Complement system in diseases Open access 8 citations Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function 2024 International Journal of Molecular Sciences article Immunology and Microbiology Complement system in diseases Open access 4 citations Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria 2024 American Journal of Hematology article Immunology and Microbiology Complement system in diseases Open access 52 citations Efficacy, Safety, and Quality of Life of Pegcetacoplan in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria Treated within the Phase 3 PEGASUS Trial 2024 Acta Haematologica article Immunology and Microbiology Complement system in diseases Open access 4 citations Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria 2024 Blood Advances article Immunology and Microbiology Complement system in diseases Open access 18 citations Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria 2024 Hematology article Immunology and Microbiology Complement system in diseases Open access 22 citations Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case–control study in the International PNH Registry 2023 Annals of Hematology article Immunology and Microbiology Complement system in diseases Open access 19 citations Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long‐term results from the phase I/II COMPOSER trial 2023 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access 20 citations Fatigue and health‐related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data 2023 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access 6 citations Mitigating Drug–Target–Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors 2023 Clinical Pharmacology & Therapeutics article Immunology and Microbiology Complement system in diseases Open access 10 citations Paroxysmal nocturnal hemoglobinuria: Where we stand 2023 American Journal of Hematology article Immunology and Microbiology Complement system in diseases Open access 24 citations The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective 2022 Hematology article Immunology and Microbiology Complement system in diseases Open access 12 citations Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial 2022 The Lancet Haematology article Immunology and Microbiology Complement system in diseases Open access 74 citations The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient‐reported insights on symptoms and quality of life 2022 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access 38 citations Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls 2022 Seminars in Immunology article Immunology and Microbiology Complement system in diseases 18 citations Halting targeted and collateral damage to red blood cells by the complement system 2021 Seminars in Immunopathology article Immunology and Microbiology Complement system in diseases Open access 20 citations 1–20 of 21 Page 1 / 2 Next → References 0